These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34567947)

  • 41. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
    Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
    Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
    Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
    Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.
    Fabi A; Russillo M; Ferretti G; Metro G; Nisticò C; Papaldo P; De Vita F; D'Auria G; Vidiri A; Giannarelli D; Cognetti F
    BMC Cancer; 2012 Oct; 12():482. PubMed ID: 23083011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
    McKeage K; Perry CM
    Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Locally advanced breast cancer with bleeding - two cases effectively treated with bevacizumab plus weekly paclitaxel.
    Ishizuna K; Ninomiya J; Ogawa T; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y
    Gan To Kagaku Ryoho; 2014 May; 41(5):637-40. PubMed ID: 24917012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
    Kawalec P; Łopuch S; Mikrut A
    Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
    Saloustros E; Nikolaou M; Kalbakis K; Polyzos A; Christofillakis C; Kentepozidis N; Pistamaltzian N; Kourousis C; Vamvakas L; Georgoulias V; Mavroudis D
    Clin Breast Cancer; 2018 Feb; 18(1):88-94. PubMed ID: 29153775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis.
    Funasaka C; Naito Y; Kusuhara S; Nakao T; Fukasawa Y; Mamishin K; Komuro A; Okunaka M; Kondoh C; Harano K; Kogawa T; Matsubara N; Hosono A; Kawasaki T; Mukohara T
    Breast; 2021 Aug; 58():50-56. PubMed ID: 33901922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
    Claessens AKM; Bos MEMM; Lopez-Yurda M; Bouma JM; Rademaker-Lakhai JM; Honkoop AH; de Graaf H; van Druten E; van Warmerdam LJC; van der Sangen MJC; Tjan-Heijnen VCG; Erdkamp FLG;
    Breast Cancer Res Treat; 2018 Nov; 172(2):413-423. PubMed ID: 30121808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Combination Therapy of Bevacizumab plus Paclitaxel Was Effective for a Metastatic Choroidal Tumor Secondary to Breast Cancer in a Patient with Ocular Symptoms].
    Hattori M; Shirahane K; Sakai M; Sassa Y; Nishihara Y; Aibe H; Masuda M; Mori D
    Gan To Kagaku Ryoho; 2020 Aug; 47(8):1221-1224. PubMed ID: 32829359
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
    Smyth LM; Iyengar NM; Chen MF; Popper SM; Patil S; Wasserheit-Lieblich C; Argolo DF; Singh JC; Chandarlapaty S; Sugarman SM; Comen EA; Drullinsky PR; Traina TA; Troso-Sandoval T; Baselga J; Norton L; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2016 Jul; 158(1):91-97. PubMed ID: 27306421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab
    Nakamoto S; Watanabe J; Ohtani S; Morita S; Ikeda M
    In Vivo; 2020; 34(3):1377-1386. PubMed ID: 32354934
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
    Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.
    Mery B; Rowinski E; Vallard A; Jacquin JP; Simoens X; Magné N; Doucey P
    Oncology; 2019; 97(1):1-6. PubMed ID: 30939479
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.
    Xu BH; Jiang ZF; Shen ZZ; Guan ZZ; Chen ZD; Cheng Y; Zheng H; Jiang J; Wang XJ; Tong ZS; Qin SK; Luo Y; Yao M; Wang LW; He J
    Chin Med J (Engl); 2012 Mar; 125(5):764-9. PubMed ID: 22490570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
    Van Raemdonck E; Floris G; Berteloot P; Laenen A; Vergote I; Wildiers H; Punie K; Neven P
    Breast Cancer Res Treat; 2021 Jan; 185(1):183-194. PubMed ID: 32980945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Neoadjuvant Epirubicin-Cyclophosphamide Therapy followed by Nab-Paclitaxel in Patients with Operable Breast Cancer-A Single-Center Phase Ⅱ Trial].
    Ogata R; Yamamoto Y; Jo A; Fukuma Y; Mikami T; Kawano S; Kishino E; Saito W; Koike Y; Soda M; Nomura T; Tanaka K; Kurebayashi J
    Gan To Kagaku Ryoho; 2022 Jun; 49(6):677-682. PubMed ID: 35799395
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.
    Pizzuti L; Sergi D; Sperduti I; Lauro LD; Mazzotta M; Botti C; Izzo F; Marchetti L; Tomao S; Marchetti P; Natoli C; Grassadonia A; Gamucci T; Mentuccia L; Magnolfi E; Vaccaro A; Cassano A; Rossi E; Botticelli A; Sini V; Sarobba MG; Fabbri MA; Moscetti L; Astone A; Michelotti A; De Angelis C; Bertolini I; Angelini F; Ciliberto G; Maugeri-Saccà M; Giordano A; Barba M; Vici P
    Cancer Biol Ther; 2018 Apr; 19(4):328-334. PubMed ID: 29336662
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
    Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
    Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.